poisar

Stock

Theriva Biologics, Inc. TOVX

$0.24+1.12%

Overview

TOVX market data

Price History

TOVX price chart · 1M
O
0.242400
H
0.244500
L
0.238800
C
0.243900
Vol
8,406.00
Source
US equities market feed
Observed
Aug 26, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$0.24
Previous Close
$0.24
Day High
$0.24
Day Low
$0.24
52 Week High
$0.49
52 Week Low
$0.18
7 Day Return
+5.04%
30 Day Return
+12.34%
90 Day Return
-22.05%
1 Year Return
+9.96%
Daily Notional Volume
$2.1K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.96
Diluted earnings per share over the trailing twelve months.
Beta
1.19
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-681.3%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.16 – $0.86
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $10.6M · P/B 0.46 · P/S 35.18.

Company News

7 captured
8-K filing — Theriva Biologics, Inc. (TOVX)SEC EDGAR · Aug 11, 2026, 12:10 PM
Theriva Biologics Q2 EPS $(0.07) Misses $(0.05) EstimateBenzinga · Aug 11, 2026, 12:06 PM
Theriva Biologics Doses First Patient In VIRAGE2 Phase 2a Clinical Trial, Small Proof-Of-Concept Study Evaluating More Frequent Repeated Dosing Of VCN-01 In First-Line Metastatic PDAC Patients Treated With Gemcitabine/Nab-Paclitaxel ChemotherapyBenzinga · Aug 6, 2026, 12:08 PM
Theriva Biologics Receives Spanish Agency Of Medicines And Medical Devices Authorization To Initiate Its VIRAGE2 Clinical TrialBenzinga · Jul 7, 2026, 12:15 PM
Theriva Biologics shares are trading higher after the company announced the publication of clinical, translational results from VCN-01's Phase 1 clinical trial in Head & Neck Squamous Cell Carcinoma in Clinical Cancer Research journal.Benzinga · Jun 11, 2026, 12:46 PM
Theriva Biologics Announces Publication Of Clinical, Translational Results From VCN-01's Phase 1 Clinical Trial In Head & Neck Squamous Cell Carcinoma In Clinical Cancer Research JournalBenzinga · Jun 11, 2026, 12:43 PM
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer ResearchGlobenewswire Inc · Jun 11, 2026, 12:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock